TransMedics logo

TransMedicsNASDAQ: TMDX

Profile

Sector:

Healthcare

Country:

United States

IPO:

02 May 2019

Next earnings report:

26 February 2025

Last dividends:

N/A

Next dividends:

N/A
$2.76 B
-53%vs. 3y high
84%vs. sector
-98%vs. 3y high
87%vs. sector
-62%vs. 3y high
95%vs. sector
-80%vs. 3y high
67%vs. sector

Price

after hours | Fri, 01 Nov 2024 23:58:59 GMT
$82.15-$0.75(-0.90%)

Dividend

No data over the past 3 years
$108.76 M$113.44 M
$108.76 M$4.22 M

Analysts recommendations

Institutional Ownership

TMDX Latest News

TMDX INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Announces Investigation into TransMedics Group, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
prnewswire.com01 November 2024 Sentiment: NEGATIVE

SAN DIEGO , Nov. 1, 2024 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving TransMedics Group, Inc. (NASDAQ: TMDX) focused on whether the company and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the TransMedics investigation or if you are a TransMedics investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-transmedics-group-inc-investigation-tmdx.html   You can also contact attorneys J.C.

TransMedics (TMDX) Reports Q3 Earnings: What Key Metrics Have to Say
zacks.com30 October 2024 Sentiment: POSITIVE

Although the revenue and EPS for TransMedics (TMDX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
prnewswire.com29 October 2024 Sentiment: POSITIVE

ANDOVER, Mass. , Oct. 29, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 23, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 2,969 shares of its common stock and an aggregate of 1,937 restricted stock units to 6 employees, each as a material inducement for each employee's entry into employment with TransMedics.

TransMedics: Every Hero Becomes A Bore At Last
seekingalpha.com29 October 2024 Sentiment: NEGATIVE

TransMedics Group, Inc. faces significant challenges due to aircraft maintenance issues and rising aviation costs, leading to a 42% stock price drop and a HOLD rating. Revenue shortfall is attributed to a national decline in transplant volumes and reduced service component charges, impacting margins and overall financial performance. The company's aviation operations are struggling with unscheduled maintenance, reducing operational aircraft and causing missed revenue opportunities.

TransMedics Stock Falls as Q3 Earnings & Sales Miss Estimates
zacks.com29 October 2024 Sentiment: NEUTRAL

TMDX's third-quarter revenues increase with the utilization of the OCS across all three organs and additional revenues generated by its logistics services. Gross margin contracts.

These Analysts Cut Their Forecasts On TransMedics Group Following Weak Results
benzinga.com29 October 2024 Sentiment: NEGATIVE

TransMedics Group, Inc. TMDX posted downbeat quarterly results on Monday.

INVESTIGATION ALERT (NASDAQ:TMDX): DiCello Levitt LLP Is Investigating Investor Claims Against TransMedics Group, Inc. and Encourages TMDX Investors with Losses to Contact the Firm
globenewswire.com28 October 2024 Sentiment: NEGATIVE

SAN DIEGO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- DiCello Levitt LLP announces that it is investigating whether TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ:TMDX) complied with federal securities laws. The Firm's investigation focuses on whether the Company violated the federal securities laws, issued false and/or misleading statements, and/or failed to disclose information required to be disclosed to investors.

TransMedics Group, Inc. (TMDX) Q3 2024 Earnings Call Transcript
seekingalpha.com28 October 2024 Sentiment: POSITIVE

TransMedics Group, Inc. (NASDAQ:TMDX ) Q3 2024 Earnings Conference Call October 28, 2024 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group, Investor Relations Waleed Hassanein - President and Chief Executive Officer Stephen Gordon - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan William Plovanic - Canaccord Joshua Jennings - TD Cowen Ryan Daniels - William Blair Matthew O'Brien - Piper Sandler Suraj Kalia - Oppenheimer & Company David Rescott - Baird Mike Matson - Needham & Company Operator Good afternoon and welcome to the TransMedics Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

TransMedics (TMDX) Q3 Earnings and Revenues Miss Estimates
zacks.com28 October 2024 Sentiment: NEGATIVE

TransMedics (TMDX) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to loss of $0.12 per share a year ago.

TransMedics Reports Third Quarter 2024 Financial Results
prnewswire.com28 October 2024 Sentiment: POSITIVE

ANDOVER, Mass. , Oct. 28, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2024.

What type of business is TransMedics?

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

What sector is TransMedics in?

TransMedics is in the Healthcare sector

What industry is TransMedics in?

TransMedics is in the Medical Devices industry

What country is TransMedics from?

TransMedics is headquartered in United States

When did TransMedics go public?

TransMedics initial public offering (IPO) was on 02 May 2019

What is TransMedics website?

https://www.transmedics.com

Is TransMedics in the S&P 500?

No, TransMedics is not included in the S&P 500 index

Is TransMedics in the NASDAQ 100?

No, TransMedics is not included in the NASDAQ 100 index

Is TransMedics in the Dow Jones?

No, TransMedics is not included in the Dow Jones index

When was TransMedics the previous earnings report?

No data

When does TransMedics earnings report?

The next expected earnings date for TransMedics is 26 February 2025